Insider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Buys $98,400.00 in Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur purchased 20,000 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was bought at an average cost of $4.92 per share, with a total value of $98,400.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,266,424 shares of the company’s stock, valued at approximately $16,070,806.08. This trade represents a 0.62 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Nuvectis Pharma Stock Performance

NASDAQ NVCT opened at $5.07 on Thursday. The stock’s 50-day simple moving average is $7.07 and its two-hundred day simple moving average is $6.76. Nuvectis Pharma, Inc. has a twelve month low of $4.75 and a twelve month high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. During the same period in the previous year, the company posted ($0.37) EPS. Research analysts predict that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of Nuvectis Pharma in a research note on Tuesday, August 6th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Nuvectis Pharma in the second quarter worth about $58,000. Nations Financial Group Inc. IA ADV bought a new stake in shares of Nuvectis Pharma in the third quarter worth about $63,000. Baxter Bros Inc. bought a new stake in shares of Nuvectis Pharma in the second quarter worth about $79,000. GSA Capital Partners LLP grew its stake in shares of Nuvectis Pharma by 3.7% in the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after purchasing an additional 1,790 shares during the last quarter. Finally, Iridian Asset Management LLC CT bought a new stake in shares of Nuvectis Pharma in the third quarter worth about $348,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.